Concord Biotech (NSE:CONCORDBIO) and Fermentation APIs
NiveshIQ
NSE: CONCORDBIO · IT
Concord Biotech Ltd.
₹1,505.70▲ ₹52.90 (+3.64%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CONCORDBIO. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Concord Biotech Ltd.
Concord Biotech Limited is a biopharma company that engages in research and development, manufacture, and sale of pharmaceutical products in India and internationally. The company operates through two segments: Active Pharmaceutical Ingredients (APIs) and Formulations. It provides a diverse portfolio of products, including immunosuppressants, anti-bacterial, oncology, and antifungal drugs. The company has reported a 26.23% year-over-year increase in consolidated net sales to Rs 257.49 crore in June 2026. This growth is driven by the strength of its API segment. Concord Biotech has a competitive position in the Indian and international pharmaceutical markets, with a strong product portfolio and a growing presence in key therapeutic areas. The company's growth outlook appears positive, with
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,017 Cr +19.20% | ₹1,200 Cr +18.00% | ₹1,055 Cr -12.10% |
| EBITDA Margin | 41.89% | 41.83% | 39.79% |
| Net Profit | ₹308.00 Cr +28.30% | ₹372.00 Cr +20.80% | ₹259.23 Cr -30.30% |
| EPS | ₹29.45 | ₹35.52 | ₹24.78 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Concord Biotech (NSE:CONCORDBIO) and Fermentation APIs
Concord Biotech expects FY27 growth to exceed historical rates
🔒
+ 3 more stories about Concord Biotech Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹257 Cr, PAT ₹58 Cr, EPS ₹5.52, EBITDA margin 37.0%. Growth context: revenue QoQ -21.0%, PAT QoQ -34.8%. Street verdict: inline, revenue surprise +5.0%, PAT surprise -1.5%.
Management commentary highlights the company's near-term growth drivers as product launches, approvals, and therapy-mix ...
FY26 (last completed FY): revenue ₹1, 055 Cr, PAT ₹259 Cr, EBITDA margin 39.8%, EPS ₹24.78. Year-on-year: revenue YoY -1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CONCORDBIO
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CONCORDBIO alongside your other holdings
Unlock full CONCORDBIO research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Concord Biotech Ltd.?
NiveshIQ detects active intelligence signals for Concord Biotech Ltd. (CONCORDBIO) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Concord Biotech Ltd.?
Concord Biotech Ltd. operates in the IT sector with a market capitalisation of ₹1,224,009.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.